USP2 and neoplasm: Importantly, the combinatorial scheme incorporating both USP2 and HSP90 inhibitors most potently repressed the further in vivo expansion of the HCC1954 breast cancer xenografts, which was evidenced by markedly attenuated tumor volumes and weights (Fig. 6a–c).